DNA vaccines: Roles against diseases

GERMS

Volumn 3, Issue 1, 2013, Pages 26-35

  Khan, Kishwar Hayat ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Applications; Diseases; Dna vaccine; Vaccination

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; UNCLASSIFIED DRUG; VAXFECTIN;

ANTHRAX; ANTIGEN EXPRESSION; AWARENESS; DENGUE; DISEASES; EDWARDSIELLA TARDA; GENE CONSTRUCT; GUIDELINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNITY; IMMUNOGENICITY; INFLUENZA; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; NONHUMAN; REVIEW; SAFETY; TUBERCULOSIS; TYPHOID FEVER; VACCINATION; WART VIRUS;

EID: 84886443339     PISSN: None     EISSN: 22482997     Source Type: Journal    
DOI: 10.11599/germs.2013.1034     Document Type: Review

References (84)

1. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990; 247(4949 Pt 1):1465-8. [CrossRef] [PubMed]
2. Chow YH, Chiang BL, Lee YL, et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol. 1998 Feb 1;160(3):1320-9. [PubMed]
3. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993; 259(5102):1745-9. [CrossRef] [PubMed]
4. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol. 1997;158(8):3635-9. [PubMed]
5. Khan KH. Vectors Used in Gene Manipulation - A retrospective. Advanced Biotech Journal - Online. Tutorial review. 2009; 9(2):1-8.
6. Khan KH. Gene transfer technologies in plants: Roles in improving crops. Recent Research in Science and Technology. 2009;1(3):116-23.
7. Khan KH. Gene transfer technologies leading to transgenic animals. Journal of Ecobiotechnology. 2009; 1(1): 32-40.
8. Khan KH. Gene Transfer Technologies and their Applications: Roles in Human Diseases. Asian Journal of Experimental Biological Science. 2010;1(2):208-18.
9. Manthorpe M, Cornefert-Jensen F, Hartikka J, et al. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther. 1993;4(4):419-31. [CrossRef] [PubMed]
10. Condon C, Watkins SC, Celluzzi CM, et al. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med. 1996;2(10):1122-8. [CrossRef] [PubMed]
11. Mor G, Klinman DM, Shapiro S, et al. Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol. 1995;155(4):2039-46. [PubMed]
12. Casares S, Inaba K, Brumeanu TD, et al. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med. 1997;186(9):1481-6. [CrossRef] [PubMed] [FullText]
13. Corr M, Lee DJ, Carson DA, et al. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med. 1996;184(4):1555-60. [CrossRef] [PubMed]
14. Doe B, Selby M, Barnett S, et al. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci U S A. 1996;93(16):8578-83. [CrossRef] [PubMed] [FullText]
15. Ulmer JB, Deck RR, Dewitt CM, et al. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology. 1996;89(1):59-67. [CrossRef] [PubMed] [FullText]
16. Corr M, von Damm A, Lee DJ, et al. In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol. 1999;163(9):4721-7. [PubMed]
17. Fu TM, Ulmer JB, Caulfield MJ, et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med. 1997;3(6):362-71. [PubMed] [FullText]
18. Cheng WF, Hung CF, Chen CA. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine. 2005;23(29):3864-74. [CrossRef] [PubMed] [FullText]
19. Alarcon JB, Waine GW, McManus DP. DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Adv Parasitol. 1999;42:343-410. [CrossRef]
20. Smooker PM, Rainczuk A, Kennedy N, et al. DNA vaccines and their application against parasites--promise, limitations and potential solutions. Biotechnol Annu Rev. 2004;10:189-236. [CrossRef]
21. Kennedy NJ, Spithill TW, Tennent J. DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy. Vaccine. 2006;24(7):970-9. [CrossRef] [PubMed]
22. Male D, Brostoff J, Roth DB, Roitt I. Immunology, 7th Edition, Vaccination, Chapter 18 (p 325-40), MOSBY Elsevier, 2006.
23. Kindt TJ, Goldsby RA, Osborne BA. Sixth Edition, Kuby Immunology. Vaccines Chapter 19 (p475-92), W.H.Freeman and Co, New York. 2007.
24. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol. 2012;162(2-3):171-82. [CrossRef] [PubMed]
25. Khan FA. The elements of immunology. Vaccines, Chapter 16 (p343-59). Chennai Microprint, India, 2009.
26. Doria-Rose NA, Haigwood NL. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods. 2003;31(3):207-16. [CrossRef]
27. Sasaki S, Takeshita F, Xin KQ, et al. Adjuvant formulations and delivery systems for DNA vaccines. Methods. 2003;31(3):243-54. [CrossRef]
28. Robinson HL, Pertmer TM. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res. 2000; 55:1-74. [CrossRef]
29. Sun Y, Hu YH, Liu CS, et al. Construction and analysis of an experimental Streptococcus iniae DNA vaccine. Vaccine. 2010;28(23):3905-12. [CrossRef] [PubMed]
30. Fowler VL, Barnett PV. Progress in the development of DNA vaccines against foot-and-mouth disease. Expert Rev Vaccines. 2012;11(4):481-93. [CrossRef] [PubMed]
31. Kim D, Hung CF, Wu TC, et al. DNA vaccine with α- galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine. 2010;28(45):7297-305. [CrossRef] [PubMed] [FullText]
32. Bharadwaj M, Hussain S, Nasare V, et al. HPV & HPV vaccination: issues in developing countries. Indian J Med Res. 2009;130(3):327-33. [PubMed]
33. Poláková I, Pokorná D, Dusková M, etc. DNA vaccine against human papillomavirus type 16: modifications of the E6 oncogene. Vaccine. 2010;28(6):1506-13. [CrossRef] [PubMed]
34. Changhong S, Hai Z, Limei W, et al. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene. Tuberculosis (Edinb). 2009;89(1):54-61. [CrossRef] [PubMed]
35. Wu J, Ma H, Qu Q. Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice. Vaccine. 2011;29(44):7624-30. [CrossRef] [PubMed]
36. Hu D, Wu J, Zhang R, et al. T-bet acts as a powerful adjuvant in Ag85B DNA-based vaccination against tuberculosis. Mol Med Report. 2012;6(1):139-44. [CrossRef] [PubMed]
37. Li X, Xu W, Xiong S. A novel tuberculosis DNA vaccine in an HIV-1 p24 protein backbone confers protection against Mycobacterium tuberculosis and simultaneously elicits robust humoral and cellular responses to HIV-1. Clin Vaccine Immunol. 2012;19(5):723-30. [CrossRef] [PubMed] [FullText]
38. Janda JM, Abbott SL. Infections associated with the genus Edwardsiella: the role of Edwardsiella tarda in human disease. Clin Infect Dis. 1993;17(4):742-8. [CrossRef]
39. Slaven EM, Lopez FA, Hart SM, et al. Myonecrosis caused by Edwardsiella tarda: a case report and case series of extraintestinal E. tarda infections. Clin Infect Dis. 2001; 32 (10): 1430-33. [CrossRef] [PubMed]
40. Jiao XD, Zhang M, Hu YH. Construction and evaluation of DNA vaccines encoding Edwardsiella tarda antigens. Vaccine. 2009;27(38):5195-202. [CrossRef] [PubMed]
41. Boyapalle S, Mohapatra S, Mohapatra S. Nanotechnology applications to HIV vaccines and microbicides. J Glob Infect Dis. 2012;4(1):62-68. [CrossRef] [PubMed] [FullText]
42. Hutnick NA, Myles DJ, Bian CB, et al. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol. 2011;1(4):233-40. [CrossRef] [PubMed]
43. Streinu-Cercel A. Nanoparticles. GERMS. 2012;2(3):90. [CrossRef]
44. Munang'andu HM, Banda F, Chikampa W. Risk analysis of an anthrax outbreak in cattle and humans of Sesheke district of Western Zambia. Acta Trop. 2012;124(2):162-5. [CrossRef] [PubMed]
45. Chitlaru T, Altboum Z, Reuveny S. Progress and novel strategies in vaccine development and treatment of anthrax. Immunol Rev. 2011;239(1):221-36. [CrossRef] [PubMed]
46. Kaur M, Bhatnagar R. Recent progress in the development of anthrax vaccines. Recent Pat Biotechnol. 2011;5(3):148-59. [CrossRef]
47. Albrecht MT, Eyles JE, Baillie LW. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model. FEMS Immunol Med Microbiol. 2012;65(3):505-9. [CrossRef] [PubMed]
48. Klimov AI, Garten R, Russell C, et al. WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011. Vaccine. 2012;30(45): 6461-71. [CrossRef] [PubMed]
49. Drape RJ, Macklin MD, Barr LJ, et al. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine. 2006;24(21):4475-81. [CrossRef] [PubMed]
50. Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med. 1995;1(6):583-7. [CrossRef] [PubMed]
51. Zhao K, Shi X, Zhao Y, et al. Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles Vaccine. 2011;29(47):8549-56. [CrossRef] [PubMed]
52. Park KS, Seo YB, Lee JY, et al. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Vaccine. 2011;29(33):5481-7. [CrossRef] [PubMed]
53. WHO Media Centre. Malaria. Fact sheet No.94. 2012. Accessed on: November 2, 2012. Available at: http://www.who.int/mediacentre/factsheets/fs094/en/
54. Kumar A, Chery L, Biswas C, et al. Malaria in South Asia: Prevalence and control. Acta Trop. 2012;121(3):246-55. [CrossRef] [PubMed]
55. Cherif MS, Shuaibu MN, Kurosaki T, et al. Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration. Vaccine. 2011;29(48):9038-50. [CrossRef] [PubMed]
56. Bergmann-Leitner ES, Leitner WW, Duncan EH, et al. Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis. Vaccine. 2009;27(41):5700-8. [CrossRef] [PubMed]
57. Sedegah M, Rogers WO, Belmonte M, et al. Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses. Vaccine. 2010;28(17):3055-65. [CrossRef] [PubMed]
58. Solomons HD, Joubert CG, Beichter B, et al. The winding road to developing a malaria vaccine. Study hypothesis. GERMS. 2012;2(3):91-4. [CrossRef]
59. Wright WF, Pritt BS. Update: The diagnosis and management of dengue virus infection in North America. Diagn Microbiol Infect Dis. 2012;73(3):215-20. [CrossRef] [PubMed]
60. Lorenz IC, Allison SL, Heinz FX, et al. Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J Virol. 2002;76(11):5480-91. [CrossRef] [PubMed] [FullText]
61. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol. 2005;3(1):13-22. [CrossRef] [PubMed]
62. Danko JR, Beckett CG, Porter KR. Development of dengue DNA vaccines. Vaccine. 2011;29(42):7261-6. [CrossRef] [PubMed]
63. Hughes HR, Crill WD, Davis BS, et al. A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines. Virology. 2012;424(2):129-37. [CrossRef] [PubMed]
64. Porter KR, Ewing D, Chen L, et al. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine. Vaccine. 2012;30(2):336-41. [CrossRef] [PubMed]
65. Dhanashekar R, Akkinepalli S, Nellutla A. Milk-borne infections. An analysis of their potential effect on the milk industry. GERMS. 2012;2(3):101-9. [CrossRef]
66. Khan KH. Recent trends in typhoid research-a review. International Journal of Biosciences. 2012;2(3):110-20.
67. Khan KH. Emblica officinalis reduces the initiation of oxidative stress by Salmonella typhimurium in mice and can be used in typhoid. Lat Am J Pharm. 2010;29(2):171-7.
68. Khan KH. Protective effect of Emblica officinalis against S typhimurium through its antioxidant activity. Recent Research in Science and Technology. 2010;2(4):29-36.
69. Khan KH. Immunomodulatory activity of Terminalia chebula against Salmonella typhimurium in mice. Recent Research in Science and Technology. 2009;1(5):211-16.
70. Khan KH, Ganjewala D, Jain SK. Pretreatment with Emblica officinalis can reduce typhoid risk. Trendz in BioTech. 2008; 4(5): 15-21.
71. Khan KH. Terminalia chebula reduces the oxidative stress induced by salmonella typhimurium in mice and may reduce the risk of getting typhoid. Advances in Biological Research. 2009;3(1-2):1-8.
72. Khan KH. Roles of Emblica officinalis in medicine - A review. Botany Research International. 2009;2(4):218-28.
73. Khan KH. The effect of regular intake of Terminalia chebula on oxidative stress in mice originated from Salmonella typhimurium. EurAsia J BioSci. 2009;3(15):113-21. [CrossRef]
74. Khan KH, Jain SK. Regular intake of Terminalia chebula can reduce the risk of getting typhoid fever. Advanced Biotech. 2009; 8 (9): 10-15.
75. Khan KH, Ganjewala D. Recent advancement in typhoid research - a review. Advanced Biotech. 2008;7(4):35-41.
76. Khan KH, Prasad BN, Ganjewala D, Jain SK. Efficacy of lyophilized juice of Emblica officinalis against experimentally induced salmonellosis. Recent Advances in Biotechnology. 2008; 136-43.
77. Khan KH, Madani A, Jain SK. Infectious diseases and herbal drugs. Compendium of Invited lectures. World Ayurveda Congress. 2002; 64-76.
78. Khan KH, Jain SK. Medicinal Plants a retrospective. Hamdard Medicus. 2003; XLVI(3): 23-33.
79. Marathe SA, Lahiri A, Negi VD, et al. Typhoid fever & vaccine development: a partially answered question. Indian J Med Res. 2012;135:161-9. [PubMed] [FullText]
80. Brocato R, Josleyn M, Ballantyne J, et al. DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS). PLoS One. 2012;7(4):e35996. [CrossRef] [PubMed] [FullText]
81. Masih S, Arora SK, Vasishta RK. Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis. Exp Parasitol. 2011;129(1):55-64. [CrossRef] [PubMed]
82. Zeng Q, Gomez BP, Viscidi RP, et al. Development of a DNA vaccine targeting Merkel cell polyomavirus. Vaccine. 2012;30(7):1322-9. [CrossRef] [PubMed]
83. Sun Y, Zhang M, Liu C, et al. A divalent DNA vaccine based on Sia10 and OmpU induces cross protection against Streptococcus iniae and Vibrio anguillarum in Japanese flounder. Fish Shellfish Immunol. 2012;32(6):1216-22. [CrossRef] [PubMed]
84. Klinman DM, Klaschik S, Tross D. FDA guidance on prophylactic DNA vaccines: analysis and recommendations. Vaccine. 2010;28(16):2801-5. [CrossRef] [PubMed] [FullText]